| 
      
        | Histology | MRI | LOH9p,10q,17p | 1p/19qCo-Del | EGFRAmpl | PTEN, TP53,
 TERTMut
 | MGMTMeth |  
        | Enhancing    tumor | CE | + | + | ++ | ++ | + |  
        | Tumor    infiltration with MVP | CE/NE | + | + | + | + | + |  
        | Tumor    infiltration | CE/NE | +/– | – | + | – | – |  
        | Edema with or    without infiltration | NE | – | – | – | – | – |  | 
  
    | MRI: magnetic resonance imaging; MVP: microvascular proliferation; CE: contrast
enhancing; NE: non-contrast enhancing; LOH: loss of heterozygosity: EGFR:
epidermal growth factor receptor; PTEN: phosphatase and tensin homologue;
TP53: tumor protein p53; TERT, telomerase reverse transcriptase; MGMT: O6-
methylguanine-DNA methylatransferase. Note: LOH: The scale corresponds to the occurrence (+) or absence (–) of LOH on
the tested regions; EGFR: The scale corresponds to the number of samples with
gene amplification (++, 100%; +, <50%; –, no amplification); PTEN, TP53, TERT:
The scale corresponds to the number of samples with gene mutations (–, wild
type); MGMT: The scale corresponds to the number of samples with (+) or without
(–) promoter methylation.
 | 
  
    | Table 2: Comparison among histologic patterns, MRI and molecular genetics. |